These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 35943716)

  • 1. Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.
    Bozorgi A; Bozorgi M; Khazaei M
    Cell Oncol (Dordr); 2022 Oct; 45(5):755-777. PubMed ID: 35943716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
    Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P
    Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor (CAR) T-cell Therapy: A New Genetically Engineered Method of Immunotherapy for Cancer.
    Singh AK; Malviya R; Singh A; Sundram S; Mishra S
    Curr Cancer Drug Targets; 2023; 23(3):199-210. PubMed ID: 36173082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.
    Nikoo M; Rudiansyah M; Bokov DO; Jainakbaev NT; Suksatan W; Ansari MJ; Thangavelu L; Chupradit S; Zamani A; Adili A; Shomali N; Akbari M
    J Cell Mol Med; 2022 Aug; 26(15):4137-4156. PubMed ID: 35762299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.
    Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
    Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.
    Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H
    Front Immunol; 2022; 13():887471. PubMed ID: 35935930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
    Yu T; Yu SK; Xiang Y; Lu KH; Sun M
    Front Immunol; 2022; 13():936496. PubMed ID: 35903099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
    Dagar G; Gupta A; Masoodi T; Nisar S; Merhi M; Hashem S; Chauhan R; Dagar M; Mirza S; Bagga P; Kumar R; Akil ASA; Macha MA; Haris M; Uddin S; Singh M; Bhat AA
    J Transl Med; 2023 Jul; 21(1):449. PubMed ID: 37420216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer.
    He Q; Hu H; Yang F; Song D; Zhang X; Dai X
    Biomed Pharmacother; 2023 Jun; 162():114609. PubMed ID: 37001182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
    Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
    Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
    J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bright future or blind alley? CAR-T cell therapy for solid tumors.
    Zhang K; Chen H; Li F; Huang S; Chen F; Li Y
    Front Immunol; 2023; 14():1045024. PubMed ID: 36761757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor buster - where will the CAR-T cell therapy 'missile' go?
    Qu C; Zhang H; Cao H; Tang L; Mo H; Liu F; Zhang L; Yi Z; Long L; Yan L; Wang Z; Zhang N; Luo P; Zhang J; Liu Z; Ye W; Liu Z; Cheng Q
    Mol Cancer; 2022 Oct; 21(1):201. PubMed ID: 36261831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
    Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
    Front Immunol; 2022; 13():871661. PubMed ID: 35911706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?
    Schoenfeld AJ; O'Cearbhaill RE
    Cancer J; 2021 Mar-Apr 01; 27(2):134-142. PubMed ID: 33750073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-T cell therapy in melanoma: A future success story?
    Simon B; Uslu U
    Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
    Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
    Siegler EL; Wang P
    Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.